oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 54 )

2018 ( 96 )

2017 ( 97 )

2016 ( 161 )

Custom range...

Search Results: 1 - 10 of 44981 matches for " Michael Hummel "
All listed articles are free for downloading (OA Articles)
Page 1 /44981
Display every page Item
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies
Matthias Meier, Michael Hummel
Vascular Health and Risk Management , 2009, DOI: http://dx.doi.org/10.2147/VHRM.S4808
Abstract: rdiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies Review (6627) Total Article Views Authors: Matthias Meier, Michael Hummel Published Date October 2009 Volume 2009:5 Pages 859 - 871 DOI: http://dx.doi.org/10.2147/VHRM.S4808 Matthias Meier,1,2 Michael Hummel3,4 1Clinic for Hypertension and Nephrology, Hannover, Germany; 2Department of Nephrology, Hannover Medical School, Hannover, Germany; 3Academic Hospital Schwabing, Munich, Germany; 4Diabetes Research Institute, Munich, Germany Abstract: Type 2 diabetes mellitus (T2DM) is associated with a high risk of complications, essentially macrovascular events. Surprisingly, the effect of improved glucose control on coronary and cerebrovascular complications and the target level of glycated hemoglobin (HbA1c) in this population remains questionable. We here report the results of 4 recently published randomized controlled trials (ACCORD, ADVANCE, VADT, UKPDS post-trial), which did not demonstrate a significant reduction of cardiovascular events in the intensive group compared to the standard group. On the contrary, in ACCORD, the study with the most ambitious goal (HbA1c < 6%), the overall and cardiovascular mortality was greater in the intensive group, although the risk of microangiopathic complications, especially nephropathy, was significantly decreased. VADT suggests that one possibility for the lack of observed effect of intensive therapy could be that the cardiovascular benefit is delayed. This contrasts strongly with the long-term postintervention outcomes of UKPDS, which show a persistent benefit of glycemic control during 10 years of post-trial follow-up (‘legacy effect’). Therefore, the best way to protect patients with T2DM against coronary and cerebrovascular disease is to target all cardiovascular risk factors as early as possible by an individualized approach.
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies
Matthias Meier,Michael Hummel
Vascular Health and Risk Management , 2009,
Abstract: Matthias Meier,1,2 Michael Hummel3,41Clinic for Hypertension and Nephrology, Hannover, Germany; 2Department of Nephrology, Hannover Medical School, Hannover, Germany; 3Academic Hospital Schwabing, Munich, Germany; 4Diabetes Research Institute, Munich, GermanyAbstract: Type 2 diabetes mellitus (T2DM) is associated with a high risk of complications, essentially macrovascular events. Surprisingly, the effect of improved glucose control on coronary and cerebrovascular complications and the target level of glycated hemoglobin (HbA1c) in this population remains questionable. We here report the results of 4 recently published randomized controlled trials (ACCORD, ADVANCE, VADT, UKPDS post-trial), which did not demonstrate a significant reduction of cardiovascular events in the intensive group compared to the standard group. On the contrary, in ACCORD, the study with the most ambitious goal (HbA1c < 6%), the overall and cardiovascular mortality was greater in the intensive group, although the risk of microangiopathic complications, especially nephropathy, was significantly decreased. VADT suggests that one possibility for the lack of observed effect of intensive therapy could be that the cardiovascular benefit is delayed. This contrasts strongly with the long-term postintervention outcomes of UKPDS, which show a persistent benefit of glycemic control during 10 years of post-trial follow-up (‘legacy effect’). Therefore, the best way to protect patients with T2DM against coronary and cerebrovascular disease is to target all cardiovascular risk factors as early as possible by an individualized approach.Keywords: glycemic control, cardiovascular, ACCORD, ADVANCE, VADT, UKPDS post-trial
Evidence as Opinions of Experts
Robert Hummel,Michael Landy
Computer Science , 2013,
Abstract: We describe a viewpoint on the Dempster/Shafer 'Theory of Evidence', and provide an interpretation which regards the combination formulas as statistics of the opinions of "experts". This is done by introducing spaces with binary operations that are simpler to interpret or simpler to implement than the standard combination formula, and showing that these spaces can be mapped homomorphically onto the Dempster/Shafer theory of evidence space. The experts in the space of "opinions of experts" combine information in a Bayesian fashion. We present alternative spaces for the combination of evidence suggested by this viewpoint.
光学纯(4S,5R)-4-甲基-5-羟基-3-羰基己酸特丁酯的化学酶促合成有机化学
吉爱国,Michael Mueller,Michael Wolberg,Werner Hummel,Christian Wandrey
有机化学 , 2002,
Abstract: 采用化学方法合成了4-甲基-3,5-二羰基己酸特丁酯。以Lactobacillusbrevis醇脱氢醇为生物催化剂,选择性地将4-甲基-3,5-二羰基己酸特丁酯还原为(4S,5R)-4-甲基-5-羟基-3-羰基己酸特丁酯(99.2%ce,sym:anti=97:3)。
1,4-Diazabicyclo[2.2.2]octane (DABCO) 5-aminotetrazolates
Gerhard Laus,Volker Kahlenberg,Klaus Wurst,Michael Hummel,Herwig Schottenberger
Crystals , 2012, DOI: 10.3390/cryst2010096
Abstract: The crystal structures of four salts of 1,4-diazabicyclo[2.2.2]octane (DABCO) and 5-aminotetrazole are described. Anhydrous 1:1 ( Pbca, R gt = 0.041) and 1:2 ( P, R gt = 0.038) salts form hydrogen-bonded layers of anions and cations. The monohydrate of the 1:1 compound ( P2 1/ c, R gt = 0.038) shows infinite chains of DABCO cations and an undulated layer of anions and water molecules. The octahydrate of the 3:2 compound ( P2 1/ c, R gt = 0.042) features DABCO triples and clusters of four tetrazolate ions in a network of water molecules.
Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles
Robert Klopfleisch, Dido Lenze, Michael Hummel, Achim D Gruber
BMC Cancer , 2010, DOI: 10.1186/1471-2407-10-618
Abstract: Messenger RNA expression profiles of twenty-seven lymph node metastasis positive or negative canine mammary carcinomas were established by microarray analysis. Differentially expressed genes were functionally characterized and associated with molecular pathways. The findings were also correlated with published data on human breast cancer.Metastatic canine mammary carcinomas had 1,011 significantly differentially expressed genes when compared to non-metastatic carcinomas. Metastatic carcinomas had a significant up-regulation of genes associated with cell cycle regulation, matrix modulation, protein folding and proteasomal degradation whereas cell differentiation genes, growth factor pathway genes and regulators of actin organization were significantly down-regulated. Interestingly, 265 of the 1,011 differentially expressed canine genes are also related to human breast cancer and, vice versa, parts of a human prognostic gene signature were identified in the expression profiles of the metastatic canine tumors.Metastatic canine mammary carcinomas can be discriminated from non-metastatic carcinomas by their gene expression profiles. More than one third of the differentially expressed genes are also described of relevance for human breast cancer. Many of the differentially expressed genes are linked to functions and pathways which appear to be relevant for the induction and maintenance of metastatic progression and may represent new therapeutic targets. Furthermore, dogs are in some aspects suitable as a translational model for human breast tumors in order to identify prognostic molecular signatures and potential therapeutic targets.Canine mammary tumor (CMT) is the most common cancer among female dogs and often becomes fatal due to the development of distant metastases [1-3]. Metastasis to the regional lymph node is an early step in metastasis and one of the most important prognostic factors in the diagnosis of CMT, a criterion that is also valid for human breast cancer
No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms
Thomas Burmeister, Stefan Schwartz, Michael Hummel, Dieter Hoelzer, Eckhard Thiel
Retrovirology , 2007, DOI: 10.1186/1742-4690-4-11
Abstract: The sensitivity of the consensus PCR was at least between 10-2 and 10-3 with 100% specificity as demonstrated by serial dilutions of cell lines infected with either HTLV-I, HTLV-II or BLV. Fifty acute T-cell lymphoblastic leukemia (T-ALL) samples and 33 samples from patients with various rare mature T-cell neoplasms (T-PLL, Sézary syndrome and other T-NHL) were subsequently investigated. There were no cases with HTLV-I, HTLV-II or any other Deltaretroviruses.The results rule out a significant involvement of HTLV-I or HTLV-II in these disease entities and show that other related Deltaretroviruses are not likely to be involved. The newly established Deltaretrovirus PCR may be a useful tool for identifying new Deltaretroviruses.Retroviruses are the main etiologic agents in a variety of malignant diseases in animals [1]. Bovine leukemia virus (BLV) was the first Deltaretrovirus to be discovered in 1969 by electron microscopy [2], but it was not until 1985 that the first complete nucleotide sequence of an isolate was reported [3]. Since the discovery of HTLV-I [4] and HTLV-II [5] and their closely related simian counterparts STLV-I [6] and STLV-II [7] several Deltaretrovirus isolates have been described in various non-human primate species. In 1994, a third simian Deltaretrovirus, later designated as STLV-III, was identified in a Hamadryas Baboon (Papio Hamadryas) [8-10]. Until recently no human counterparts of STLV-III were known, but in 2005 two independent research groups described human isolates that showed high homology to STLV-III and were considered to be HTLV-III isolates [11,12]. Moreover, a fourth Deltaretrovirus was identified in a single human individual from the Rain Forest in Cameroon. It did not show sufficient homology to be classified as primate T-cell lymphotropic virus (PTLV) type I, II or III and was thus considered to be a species representative of a hitherto unknown putative PTLV-IV virus group [12].HTLV-I and STLV-I are etiologically linked to the
Prognostic Biomarkers and EBV Infection Research in Diffuse Large B-Cell Lymphoma of the Palatine Tonsils
Marinho Marques,Estela Luz,Michael Hummel,Maria das Gra?as Vieira
ISRN Oncology , 2012, DOI: 10.5402/2012/652682
Abstract:
Crystal Structure of 2-Ethylimidazole-1-sulfonyl Azide: A New Azidation Reagent
Gerhard Laus,Verena Adamer,Michael Hummel,Volker Kahlenberg,Klaus Wurst,Sven Nerdinger,Herwig Schottenberger
Crystals , 2012, DOI: 10.3390/cryst2010118
Abstract: Crystalline 2-ethylimidazole-1-sulfonyl azide was designed as a convenient reagent with improved thermal stability for electrophilic azidation of carbanions. The compound crystallized in the monoclinic space group P2 1/ c. The molecules are arranged into chains by short C–H...O contacts along a two-fold screw axis. The quaternary 1-azidosulfonyl-2-ethyl-3-methylimidazolium tetrafluoroborate crystallized in Fdd2 with two independent ion pairs which engage in C–H...F interactions.
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
Isrid Sturm, Andrew G Bosanquet, Michael Hummel, Bernd D?rken, Peter T Daniel
BMC Cancer , 2005, DOI: 10.1186/1471-2407-5-105
Abstract: 138 B-CLL samples were analysed by SSCP-PCR and sequencing for single nucleotide polymorphism at codon 72 of the p53 gene. The in vitro cytotoxicity assay (DiSC-assay) was performed with 7 drugs (chlorambucil, mafosfamide, fludarabine phosphate, methylprednisolone, doxorubicin, vincristine) or γ-irradiation.Of the138 B-CLL samples, 9 samples were homozygous for proline (Pro/Pro), 78 samples homozygous for arginine (Arg/Arg), and 49 samples heterozygous (Arg/Pro). No differences were found for patient survival and cell death triggered by 7 cytotoxic drugs or γ-irradiation.These data indicate that polymorphic variants of p53 codon 72 are not clinically relevant for apoptosis induction or patient survival in B-CLL.The tumor suppressor gene p53 plays a central role in the induction of cell cycle arrest, senescence and apoptosis [1-5]. The polyproline domain (PP domain) of p53 spanning amino acids 62–91 is involved in apoptosis induction and facilitates transactivation of pro-apoptotic genes by p53 [6].Located in this PP domain is at codon 72 a common single nucleotide polymorphism (SNP), resulting in either a proline residue (p53Pro) or an arginine residue (p53Arg). Thus, each individual inherits a p53 genotype that can be heterozygous (Arg/Pro) or homozygous for either arginine (Arg/Arg) or proline (Pro/Pro). The polymorphism is balanced, varies with latitude and race, and is maintained at different allelic frequencies across the population [7]. These two SNPs appear to be different both biochemically and biologically [8-11]. Differences in apoptosis susceptibility to cytotoxic drugs were described [12,13], and the response and survival to radiochemotherapy in clinical samples of squamous cell carcinomas was found to be increased in case the arginine allele is retained [13].Chronic lymphocytic B-cell lymphoma is still an incurable disease and may be addressed as a disease of intrinsic apoptosis deficiency. It is a disease where the mutational status of the p53 gene is
Page 1 /44981
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.